Indian Pharmas Cleared Of Price-Fixing By U.K. Court
This article was originally published in PharmAsia News
A U.K. court denied price-collusion allegations against five pharmaceuticals, including at least two with Indian ties. Goldshield, founded by India's Ajit Patel, and Ranbaxy U.K. were among firms that had been under investigation on price-fixing allegations for more than six years by the Serious Fraud Office. A U.K. court cleared the companies of a conspiracy allegation brought by the National Health Service concerning the prices of antibiotics and other common drugs. The court decided the allegations involved actions that allegedly occurred before the U.K. adopted a law making price-fixing an offense. (Click here for more
You may also be interested in...
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.
HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe.